Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM.

Next Previous
Trial Profile

Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Hyaluronidase; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Halozyme Therapeutics

Most Recent Events

  • 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrails.gov.
  • 28 Jun 2010 Acutal patient number (n=23) as reported by ClinicalTrials.gov.
  • 07 May 2010 Results will be presented at the President's Poster Session at the American Diabetes Association (ADA) 70th Scientific Sessions, as reported by Halozyme Therapeutics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top